

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Jiangsu Recbio Technology Co., Ltd.**

**江蘇瑞科生物技術股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2179)**

**PROPOSED ELECTION OF DIRECTORS OF  
THE SECOND SESSION OF THE BOARD  
AND**

**PROPOSED ELECTION OF NON-EMPLOYEE REPRESENTATIVE  
SUPERVISORS OF THE SECOND SESSION OF THE SUPERVISORY BOARD**

This announcement is made by Jiangsu Recbio Technology Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

**PROPOSED ELECTION OF DIRECTORS OF THE SECOND SESSION OF THE BOARD**

Given that the term of office of the first session of the board of directors of the Company (the “**Board**”) shall expire in May 2024, in order to maintain the normal operation of the Board and according to the requirements of the Company Law of the People's Republic of China and the Articles of Association of Jiangsu Recbio Technology Co., Ltd. (the “**Articles of Association**”), Dr. LIU Yong, Mr. LI Bu, Ms. CHEN Qingqing and Dr. HONG Kunxue have been nominated as the executive director candidates of the second session of the Board, Dr. WANG Ruwei, Dr. ZHANG Jiaxin, Dr. ZHOU Hongbin and Mr. HU Houwei have been nominated as the non-executive director candidates of the second session of the Board, and Dr. XIA Lijun, Mr. LIANG Guodong, Professor GAO Feng and Professor YUEN Ming Fai have been nominated as the independent non-executive director candidates of the second session of the Board on the Board meeting held on April 15, 2024. The term of office of Directors of the second session of the Board is three years and shall come into effect on the date of the approval of relevant resolutions at the general meeting of the Company, which shall be eligible for re-election upon the expiry of his/her term of office.

The biographies of above-mentioned director candidates are set out in Appendix I of this announcement.

The Company will enter into a director service contract with the above-mentioned persons respectively upon the approval of the general meeting of the Company. Dr. LIU Yong, Mr. LI Bu, Ms. CHEN Qingqing and Dr. HONG Kunxue receive remuneration according to their positions in the Company, and their allowance for executive Directors is HK\$320,000/year (before tax) shall be included in their total remuneration paid for their positions in the Company. Dr. WANG Ruwei, Dr. ZHANG Jiabin, Dr. ZHOU Hongbin and Mr. HU Houwei will not receive remuneration from the Company as non-executive Directors except for reasonable remuneration paid to them based on the specific services rendered to the Company by them and upon completion of the necessary decision-making process. Allowance for Dr. XIA Lijun, Mr. LIANG Guodong, Professor GAO Feng and Professor YUEN Ming Fai as independent non-executive Directors is HK\$320,000/year (before tax).

As at the date of this announcement, Dr. LIU Yong was (i) the general partner of each of Taizhou Yuangong Technology Partnership (Limited Partnership) (泰州元工科技合夥企業(有限合夥)), Taizhou Baibei Biotechnology Partnership (Limited Partnership) (泰州百倍生物科技合夥企業(有限合夥)), Taizhou Guquan Biotechnology Partnership (Limited Partnership) (泰州古泉生物科技合夥企業(有限合夥)) and Taizhou Ruibaitai Pharmaceutical Technology Partnership (L.P.) (泰州瑞百泰醫藥科技合夥企業(有限合夥)), and was interested in an aggregate of 72,512,138 domestic shares and 24,170,712 H shares held by these four entities. Dr. LIU Yong was deemed to be interested in the shares held by each of above four entities under the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong) (the “SFO”); (ii) as the beneficial owner, he held 193,943 domestic shares and 64,647 H shares of the Company. Therefore, Dr. LIU Yong was deemed to be interested in 72,706,081 domestic shares and 24,235,359 H shares of the Company, representing approximately 20.07% of the total number of issued shares of the Company, 46.96% of the total number of domestic shares and 7.67% of the total number of H shares of the Company under the SFO.

Save as disclosed in this announcement, as of the date of this announcement, each director candidate confirmed that (1) he/she did not hold any directorships in any other listed companies in the past three years nor did he/she have any other major appointments or professional qualifications; (2) he/she did not hold any positions in the Company or any of its subsidiaries; (3) he/she did not have any relationship with any directors, supervisors, senior management, substantial shareholders or controlling shareholders of the Company or any of its subsidiaries; and (4) he/she did not have any interest in the shares of the Company within the meaning of Part XV of the SFO.

Dr. XIA Lijun, Mr. LIANG Guodong, Professor GAO Feng and Professor YUEN Ming Fai have respectively confirmed that: (i) their independence as regards each of the factors referred to in Rule 3.13(1) to (8) of the Listing Rules; (ii) they have no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person (as such term is defined in the Listing Rules) of the Company; and (iii) there are no other factors that may affect their independence at the time of their nominations as independent non-executive Directors.

Save as disclosed in this announcement, the Board is not aware of other information on the proposed appointment of above-mentioned director candidates which shall be disclosed pursuant to the requirements set out in Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters in relation to the proposed appointment of above-mentioned director candidates that need to be brought to the attention of the Company’s shareholders.

## **PROPOSED ELECTION OF NON-EMPLOYEE REPRESENTATIVE SUPERVISORS OF THE SECOND SESSION OF THE SUPERVISORY BOARD**

Given that the term of office of the first session of the supervisory board of the Company (the “**Supervisory Board**”) shall expire in May 2024, in order to maintain the normal operation of the Supervisory Board and according to the requirements of the Company Law of the People’s Republic of China and the Articles of Association, Ms. QIAN Ranting and Mr. WANG Feizhou have been proposed to be elected as the non-employee representative Supervisors of the second session of the Supervisory Board on the Supervisory Board meeting held on April 15, 2024. The above-mentioned Supervisors will jointly form the second session of the Supervisory Board with employee representative Supervisors to be elected at the employee representatives conference of the Company. The term of office of Supervisors of the second session of the Supervisory Board is three years and shall come into effect on the date of the approval of relevant resolutions at the general meeting of the Company, which shall be eligible for re-election upon the expiry of his/her term of office.

The biographies of above-mentioned supervisor candidates are set out in Appendix II of this announcement.

The Company will enter into a supervisor service contract with Ms. QIAN Ranting and Mr. WANG Feizhou respectively upon the approval of the general meeting of the Company. Ms. QIAN Ranting and Mr. WANG Feizhou will not receive remuneration from the Company during her/his term of office unless otherwise specified in the Company’s remuneration scheme for Supervisors.

Save as disclosed in this announcement, as of the date of this announcement, each supervisor candidate confirmed that (1) he/she did not hold any directorships in any other listed companies in the past three years nor did he/she have any other major appointments or professional qualifications; (2) he/she did not hold any positions in the Company or any of its subsidiaries; (3) he/she did not have any relationship with any directors, supervisors, senior management, substantial shareholders or controlling shareholders of the Company or any of its subsidiaries; and (4) he/she did not have any interest in the shares of the Company within the meaning of Part XV of the SFO.

Save as disclosed in this announcement, the Board is not aware of other information on the proposed appointment of Ms. QIAN Ranting and Mr. WANG Feizhou which shall be disclosed pursuant to the requirements set out in Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters in relation to the proposed appointment of Ms. QIAN Ranting and Mr. WANG Feizhou that need to be brought to the attention of the Company’s shareholders.

A circular containing, amongst other things, the above resolutions together with a notice convening the general meeting, will be dispatched to the shareholders of the Company in due course.

By order of the Board  
**Jiangsu Rechio Technology Co., Ltd.**  
**Dr. LIU Yong**  
*Chairman*

Jiangsu Province, the PRC, April 15, 2024

*As at the date of this announcement, the Board comprises Dr. LIU Yong as the chairman of the Board and an executive Director, Dr. CHEN Jianping, Mr. LI Bu and Ms. CHEN Qingqing as executive Directors, Dr. HONG Kunxue, Dr. ZHOU Hongbin, Dr. ZHANG Jiaxin and Mr. HU Houwei as non-executive Directors, and Mr. LIANG Guodong, Dr. XIA Lijun, Professor GAO Feng and Professor YUEN Ming Fai as independent non-executive Directors.*

## APPENDIX I BIOGRAPHIES OF DIRECTOR CANDIDATES OF THE SECOND SESSION OF THE BOARD

### Executive Director Candidates:

**Dr. LIU Yong**, aged 51, is an executive Director of our Company and chairman of the Board of our Company. Dr. Liu founded our Group on March 7, 2011 and has been serving as a Director since January 25, 2019 and the chairman of our Board since October 2020, and was re-designated as an executive Director on June 28, 2021. He is primarily responsible for the overall management of business strategy, corporate development and research and development of our Group. Dr. Liu has been serving as the general manager of Beijing ABZYMO Biosciences Co., Ltd., a subsidiary of our Company, since March 7, 2011. Dr. Liu has been serving as the executive director of Beijing ABZYMO Biosciences Co., Ltd. since March 2011. He has been serving as the general manager and executive director of Wuhan Recbio Biotechnology Co., Ltd., a subsidiary of our Company, since September 2021, and chairman of the board of directors of Wuhan Recogen Biotechnology Co., Ltd., a subsidiary of our Company, since September 2021. He has been serving as the general manager and an executive director of Hangzhou Ruibaio Technology Company Limited (杭州瑞佰奧科技有限公司), a subsidiary of our Company, since February 2023.

Dr. Liu has over 23 years of technical and management experience in the field of novel vaccines. Dr. Liu has published over 60 publications in leading academic journals and held over 20 invention patents since 1998. Prior to the foundation of our Group, Dr. Liu worked at National Center for AIDS/STD Control and Prevention of Chinese Center for Disease Control and Prevention (中國疾病預防控制中心性病艾滋病預防控制中心) from February 2004 to September 2010 as a research professor and led the development of HIV DNA vaccine as a team leader of HIV DNA vaccine team. Dr. Liu has also worked as a visiting scholar at the NIH Vaccine Research Center in the U.S., where he carried out research on HIV.

Dr. Liu graduated from China Union Medical University (中國協和醫科大學) with a doctoral degree in pathogen biology in July 2000. Dr. Liu was a research fellow in NIH Vaccine Research Center in the U.S. from December 2006 to December 2007. Dr. Liu participated in post-doctoral research in basic medicine at Chinese Center for Disease Control and Prevention (中國疾病預防控制中心) from August 2001 to December 2003.

Dr. Liu obtained the certificate of research professor in biochemistry and molecular biology by Ministry of Health, PRC in July 2008. He was an editorial board (the sixth) member of the Chinese Journal of Microbiology and Immunology, and the only Asian member of the Young and Early Career Investigators Committee (YECIC) of the Global HIV Vaccine Enterprise (GHVE). Once elected as one of the third “Top Ten Innovative and Entrepreneurial High-level Talents” of Taizhou Medical New & Hi-tech Industrial Development Zone in May 2020, Dr. Liu was also recognized as an excellent entrepreneurial individual (創業先進個人) on the tenth anniversary of the establishment of Taizhou Medical New & Hi-tech Industrial Development Zone in May 2019.

**Mr. LI Bu**, aged 47, was appointed as a Director on March 27, 2021 and re-designated as an executive Director on June 28, 2021. He is primarily responsible for managing the daily operations of administrative, human resources, purchasing and IT departments and the strategic development of our Company. He joined our Company in April 2020 as an assistant to the general manager and human resources director and was appointed as a vice general manager on November 9, 2020. He has been serving as a director in Wuhan Recogen Biotechnology Co., Ltd., a subsidiary of our Company, since September 2021.

Prior to joining our Company, Mr. Li served as a human resources manager in KPC Pharmaceuticals, Inc. (昆藥集團股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 600422) from 1999 to May 2005. Mr. Li served as a president assistant in Walvax Biotechnology Co., Ltd. (雲南沃森生物技術有限公司), a company listed on the ChiNext Market of Shenzhen Stock Exchange (stock code: 300142) from September 2007 to June 2009. Mr. Li served as a human resources director in Yunnan Belle Shoes Limited (雲南百麗鞋業公司) from June 2009 to August 2012. Mr. Li served as a general manager in Kunming Hanyu Business Consulting Co., Ltd (昆明瀚宇商務諮詢有限公司) from April 2014 to January 2020.

Mr. Li obtained his bachelor's degree in technology economics from Central South University of Technology (中南工業大學) in the PRC in June 1999. Mr. Li obtained his master's degree in business management from Kunming University of Science and Technology (昆明理工大學) in the PRC in June 2011.

**Ms. CHEN Qingqing**, aged 41, was appointed as chief financial officer, vice general manager and secretary of the Board of our Company on May 9, 2021, appointed as a joint company secretary of the Company on June 28, 2021 and appointed as an executive Director on May 11, 2023. Ms. Chen is primarily responsible for financing activities, investor relationship, internal audit and control and corporate governance of the Group. She is also in charge of the finance and legal department.

Prior to joining our Group, Ms. Chen worked in Tencent Technology (Beijing) Co., Ltd. (騰訊科技(北京)有限公司) from May 2005 to April 2008. Ms. Chen worked as a deputy finance director in Beijing Qianxiang Wangjing Technology Development Co., Ltd. (北京千橡網景科技發展有限公司), a company listed on New York Stock Exchange (ticker symbol: RENN) from January 2009 to January 2015. Ms. Chen worked as a vice president of finance in Qufenqi (Ganzhou) Information Technology Co., Ltd. (趣分期(贛州)信息技術有限公司), a company listed on New York Stock Exchange (ticker symbol: QD) from March 2015 to April 2017. From May 2017 to September 2017, Ms. Chen worked as a senior finance director in Beike Finance Holdings (Beijing) Limited (貝殼金控控股(北京)有限公司) (currently known as Beike Finance Holdings (Beijing) Limited (貝殼金科控股(北京)有限公司)), a subsidiary of KE Holdings Inc., a company listed on New York Stock Exchange (ticker symbol: BEKE). Ms. Chen worked as the chief finance officer in Shihezi Chenshang Equity Investment Partnership (Limited Partnership) (石河子市辰尚股權投資合夥企業(有限合夥)) from November 2017 to July 2020. Ms. Chen worked as a vice president in Dmall Life (China) Network Technology Co., Ltd. (多點生活(中國)網絡科技有限公司) from August 2020 to March 2021.

Ms. Chen obtained her bachelor's degree in management and her master's degree in economics from Central University of Finance and Economics (中央財經大學) in the PRC in July 2004 and December 2017, respectively. Ms. Chen also obtained her master's degree in business administration from Peking University (北京大學) in the PRC in June 2019.

**Dr. HONG Kunxue**, aged 59, was appointed as a Director on May 9, 2021 and re-designated as a non-executive Director in July 2021. Dr. Hong has been serving as the chief scientist since June 1, 2021. Dr. Hong is primarily responsible for providing guidance and advice on R&D strategies of our Company.

Prior to joining our Group, Dr. Hong was a lecturer in examination department of Henan Medical University (河南醫科大學) in June 1995. Dr. Hong worked as a research scholar in the University of California, Los Angeles in the U.S. from August 2004 to February 2005 and a visiting scholar in Duke Human Vaccine Institute from August 2004 to August 2005. Dr. Hong worked in National Center for AIDS/STD Control and Prevention of Chinese Center for Disease Control and Prevention from December 2001 to May 2021 as a team leader of immunity team to lead immunity evaluation of vaccines and immunity research relating to HIV vaccines.

Dr. Hong obtained his bachelor's degree in clinical medicine from Henan Medical University (currently known as Zhengzhou University (鄭州大學)) in the PRC in June 1988. Dr. Hong obtained his master's degree in clinical laboratory diagnostics from Jilin Medical College (吉林醫學院) (currently known as Beihua University (北華大學)) in the PRC in July 1991. Dr. Hong obtained his doctoral degree in genetics from China Union Medical University (中國協和醫科大學) (currently known as Peking Union Medical College (北京協和醫學院)) in the PRC in July 1999. Dr. Hong participated in post-doctoral research at Chinese Center for Disease Control and Prevention (中國疾病預防控制中心) in the PRC from October 1999 to December 2001.

Dr. Hong has been a member of the Academic Committee and Degree Committee in National Center for AIDS/STD Control and Prevention of Chinese Center for Disease Control and Prevention from July 2008 to May 2021. Dr. Hong has also been a member of the editorial board of Infectious Microbes & Diseases (《感染微生物與疾病(英文)》) since 2019. Dr. Hong was awarded a certificate of honor for combating the COVID-19 by the People's Government of Hubei Province in April 2020. Dr. Hong was appointed as an Optical Valley Industry Professor by Wuhan University (武漢大學) in December 2021.

## **Non-Executive Director Candidates:**

**Dr. WANG Ruwei**, aged 57, was previously the vice president of business of the Sixth Affiliated Hospital of Wenzhou Medical University (People's Hospital of Lishui); successively served as the director, chief executive officer, vice chairman in Zhejiang Conba Pharmaceutical Co., Ltd. (浙江康恩貝製藥股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 600572) and concurrently served as the chairman of its subsidiaries and dean of its research institute from February 2002 to July 2020; has passed the public appraisal and selection by Zhejiang Chinese Medicine University and acted as a doctoral supervisor of Traditional Chinese Medicine since 2008; has been appointed as a member of Chinese Pharmacopoeia Commission (re-elected for three terms) since December 2010; served as the vice chairman and chief executive officer in Genor Biopharma Co., Ltd. (嘉和生物藥業有限公司), a company listed on the Hong Kong Stock Exchange (stock code: 06998) from March 2018 to December 2018; served as an independent director in Sichuan Huiyu Pharmaceutical Co., Ltd. (四川匯宇製藥股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 688553) from June 2020 to May 2023; served as the executive vice president in Hangzhou Tigermed Consulting Co., Ltd. (杭州泰格醫藥科技股份有限公司), a company listed on the Shenzhen Stock Exchange (stock code: 300347) and Hong Kong Stock Exchange (stock code: 03347) and concurrently acted as the chairman of its subsidiary, Hangzhou Yibai Health Management Co., Ltd. (杭州頤柏健康管理有限公司) from July 2020 to December 2021; served as an independent director of Zhejiang Shouxiangu Pharmaceutical Co., Ltd. (浙江壽仙谷醫藥股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 603896) since May 2021; served as a founding partner, managing director of Hangzhou Tailong Venture Capital Partnership (Limited Partnership) (杭州泰龍創業投資合夥企業(有限合夥)) from January 2022 to July 2023; served as an independent director of Huadong Medicine Co., Ltd. (華東醫藥股份有限公司), a company listed on the Shenzhen Stock Exchange (stock code: 000963) since June 2022; served as the head of strategy, investment, and international biomedical industrial park of Yangtze River Pharmaceutical (Group) Co., Ltd. (揚子江藥業集團有限公司) since November 2023.

Dr. Wang obtained his bachelor's degree in medicine from Zhejiang Medical University in 1989, graduate degree in management from Zhejiang University in 2003 and Executive Master of Business Administration (EMBA) degree from the University of East Asia, Macau in 2005, as well as doctoral degree in medicine from Shimane University, a national university of Japan (日本國立島根大學) in 2015.

**Dr. ZHANG Jiaxin**, aged 41, was appointed as a non-executive Director on May 11, 2023. He is primarily responsible for providing guidance and advice on corporate and business strategies. Dr. Zhang is currently a member of the Party committee, secretary of the disciplinary committee and director of the group office of Yangtze River Pharmaceutical (Group) Co., Ltd. (揚子江藥業集團有限公司) (“**Yangtze River Pharmaceutical Group**”), mainly responsible for disciplinary inspection, overall coordination, supervision, information collection, logistics and management of the tertiary industry units of the Yangtze River Pharmaceutical Group. Dr. Zhang joined Yangtze River Pharmaceutical Group in October 2011 and served as the director of the general management office of Yangtze River Pharmaceutical Group from 2011 to 2016; and the director of the legal and discipline committee of Yangtze River Pharmaceutical Group from 2016 to 2019; from 2019 to 2020, he served as the director of the legal affairs department of Yangtze River Pharmaceutical Group; from 2020 to 2021, he served as the director of the legal compliance department of Yangtze River Pharmaceutical Group; from November 2017 to the present, he has been serving as a member of the Party committee and secretary of the disciplinary committee of Yangtze River Pharmaceutical Group; from January 2022 to the present, he has been serving as the director of the group office of Yangtze River Pharmaceutical Group.

Dr. Zhang studied at Jilin University (吉林大學) from September 2002 to June 2011 and obtained a bachelor’s degree in law, a master’s degree in law and a doctoral degree in law from Jilin University in 2006, 2008 and 2011, respectively.

**Dr. ZHOU Hongbin**, aged 50, was appointed as a Director on November 2, 2020 and re-designated as a non-executive Director on June 28, 2021. He is primarily responsible for providing guidance and advice on corporate and business strategies.

From May 2005 to April 2021, Dr. Zhou successively served as investment manager, investment vice general manager, investment director, executive director and managing director of Legend Capital (君聯資本管理股份有限公司). From June 2015 to September 2021, Dr. Zhou served as a supervisor at Guangzhou KingMed Diagnostics Group Co., Ltd. (廣州金域醫學檢驗集團股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 603882). From February 2017 to March 2021, Dr. Zhou served as a director at Shanghai Atour Business Management (Group) Co., Ltd. (上海亞朵商業管理(集團)有限公司). From December 2018 to March 2021, Dr. Zhou served as a supervisor of Shanghai Genext Medical Technology Co., Ltd. (上海健耕醫藥科技股份有限公司). From April 2020 to December 2021, Dr. Zhou served as a director of Novast Laboratories, Limited (南通聯亞藥業股份有限公司) and Novast Pharmaceuticals, Ltd. (南通聯科藥業有限公司).

Dr. Zhou is concurrently serving the following positions outside our Group: a director of Jiangsu Lihua Animal Husbandry Co., Ltd. (江蘇立華牧業股份有限公司), a company listed in the ChiNext Market of Shenzhen Stock Exchange (stock code: 300761) from July 2015 to April 2023, a director of Milkyway Chemical Supply Chain Service Co., Ltd. (密爾克衛化工供應鏈服務股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 603713) from September 2015, a director of Shanghai Cell Therapy Group Co., Ltd. (上海細胞治療集團有限公司) from September 2016, a director of Pharmaron Beijing Co., Ltd. (康龍化成(北京)新藥技術股份有限公司), a company listed on the Main Board of the Stock Exchange (stock code: 03759) and in the ChiNext Market of Shenzhen Stock Exchange (stock code: 300759) from October 2016 to June 2023, a director of Ningbo Xinwan Technology Development Co., Ltd. (寧波新灣科技發展有限公司) from August 2017, a director of Chemclin Diagnostics Co., Ltd. (科美診斷技術股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 688468) from February 2018 to December 2023, a director of Joy Wing Mau Corporation Limited (鑫榮懋果業科技集團股份有限公司) from February 2019, a director of MicuRx Pharmaceuticals, Inc. (上海盟科藥業股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 688373) from October 2020 to December 2023, a supervisor of China Southern Airlines Cargo Logistics (Guangzhou) Co., Ltd. (南方航空貨運物流(廣州)有限公司) (currently known as China Southern Airlines Logistics Co., Ltd. (南方航空物流有限公司), which is held by China Southern Airlines Company Limited (中國南方航空股份有限公司) as to 55%, a listed company on the Stock Exchange (stock code: 01055), Shanghai Stock Exchange (stock code: 600029) and the New York Stock Exchange (ticker symbol: ZNH)) from February 2021, the co-chief investment officer of Legend Capital (君聯資本管理股份有限公司) from April 2021, a director of Atour Lifestyle Holdings Limited since March 2021, and a director of TriApex Laboratories Co., Ltd. from March 2023.

Dr. Zhou obtained his bachelor's degree in engineering from Wuhan University (武漢大學) in the PRC in July 1994. Dr. Zhou obtained his master's degree in engineering from Wuhan University in the PRC in June 1997. Dr. Zhou obtained his doctoral degree in management from Fudan University (復旦大學) in the PRC in July 2000.

**Mr. HU Houwei**, aged 42, was appointed as a non-executive Director on May 11, 2023. He is primarily responsible for providing guidance and advice on corporate and business strategies. Mr. Hu worked at China Merchants Bank Co., Ltd. Shenzhen Branch from July 2006 to March 2008 as a business manager in the Corporate Department; worked at the Investment Banking Division of Ping An Securities Co., Ltd. as a senior manager from April 2008 to November 2011; served as a senior business director of the Investment Banking Division of Hualin Securities Co., Ltd. from November 2011 to March 2015; and successively served as research director and head of compliance & risk control in Shenzhen Fer-Capital Investment Co., Ltd. (深圳前海沃盈投資管理有限公司) from April 2015 to the present.

Mr. Hu obtained a bachelor's degree in economics and a master's degree in economics from Nankai University (南開大學) in June 2004 and June 2006, respectively.

## **Independent Non-Executive Director Candidates:**

**Dr. XIA Lijun**, aged 47, was appointed as an independent non-executive Director on June 28, 2021. Dr. Xia is primarily responsible for supervising and providing independent judgment to our Board.

Prior to joining our Group, Dr. Xia served as a lecturer, master's supervisor, professor and doctoral supervisor of Shanghai University of Finance and Economics (上海財經大學) from March 2006 to January 2011, as a professor of Antai College of Economics and Management of Shanghai Jiao Tong University (上海交通大學安泰經管學院) since March 2011 and as the head of Department of Accountancy of Antai College of Economics and Management of Shanghai Jiao Tong University (上海交通大學安泰經管學院) from March 2011 to March 2023. From April 2015 to June 2020, Dr. Xia also served as an independent director of BBI Life Sciences Corporation, a company formerly listed on the Stock Exchange (stock code: 1035). From July 2019 to July 2022, Dr. Xia served as an independent director of Shanghai Sanyou Medical Co., Ltd. (上海三友醫療器械股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 688085). From May 2020 to May 2021, Dr. Xia worked as an independent director of Visionox Technology Inc. (維信諾科技股份有限公司), a company listed on the Shenzhen Stock Exchange (stock code: 002387). From February 2020 to January 2023, Dr. Xia served as an independent director of East Money Information Co., Ltd. (東方財富信息股份有限公司), a company listed on the Shenzhen Stock Exchange (stock code: 300059).

Dr. Xia is currently serving as a member of the Guiding Committee of Professional Education of Accountancy of the Ministry of Education of the PRC, the president of Higher Engineering College Committee under Accounting Society of China.

Dr. Xia is concurrently serving the following positions outside our Group, including as an independent director of Shenzhen Huitai Medical Equipment Co., Ltd. (深圳惠泰醫療器械股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 688617) from November 2019, an independent director of Shanghai Tongji Science & Technology Industrial Co., Ltd. (上海同濟科技實業股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 600846) from April 2020, an independent supervisor of Orient Securities Company Limited (東方證券股份有限公司), a company listed on the Stock Exchange (stock code: 3958) and Shanghai Stock Exchange (stock code: 600958) from March 2021, an independent director of Huatai Baoxing Fund Management Co., Ltd. (華泰保興基金管理有限公司) from July 2016, and an independent director of Zhejiang Sunrise Garment Group Co., Ltd. (浙江盛泰服裝集團股份有限公司) from December 2018.

Dr. Xia obtained his bachelor's degree in economics from Hangzhou Institute of Electronic Engineering (杭州電子工業學院) in July 1997. Dr. Xia received his master's degree and doctoral degree in Management (Accounting) from Shanghai University of Finance and Economics in March 2003 and March 2006, respectively, and conducted postdoctoral research at the Corporate Governance Center of the Chinese University of Hong Kong from April 2007 to August 2007, and February 2008 to August 2008.

Dr. Xia is in charge of the Masters of Accounting Training Project of the Ministry of Finance of PRC since October 2018. He served as the vice president of Higher Engineering College Committee under Accounting Society of China from October 2020 to October 2023. He was qualified as a Certified Public Accountant in China in June 2000.

**Mr. LIANG Guodong**, aged 72, was appointed as a Director on May 9, 2021 and re-designated as an independent non-executive Director on June 28, 2021. Mr. Liang is primarily responsible for supervising and providing independent judgement to our Board.

Prior to joining our Group, Mr. Liang worked as an assistant research professor in Institute of Virology of Chinese Academy of Preventive Medicine (中國預防醫學科學院病毒學研究所) from October 1987 to June 1992. Mr. Liang worked in National Institute for Viral Disease Control and Prevention in China CDC (中國疾病預防控制中心病毒病預防控制所) from September 1995 to August 2014 with his last positions as a research professor and deputy director in the institute.

Mr. Liang obtained his bachelor's degree in medicine and master's degree in medicine from Shanxi Medical College (山西醫學院) in the PRC in September 1977 and July 1987, respectively. Mr. Liang has been awarded third prize and first prize of Science and Technology Progress Award of Ministry of Health of the PRC in September 1998 and August 1999, respectively. Mr. Liang has been a member of National Planned Immunization Committee of PRC (國家計劃免疫委員會) and National Infectious Disease Standards Committee of PRC (國家傳染病標準委員會) since September 2010 and December 2013, respectively. Mr. Liang has been awarded the first prize for Science and Technology Awards of Chinese Preventive Medicine Association in December 2013 and second prize of Chinese Medicine Science and Technology Award in January 2014.

**Professor GAO Feng**, aged 63, was appointed as a Director on May 9, 2021 and re-designated as an independent non-executive Director on June 28, 2021. Professor Gao is primarily responsible for supervising and providing independent judgement to our Board.

Prior to joining our Group, Professor Gao worked in University of Birmingham, Alabama in the U.S. as a research instructor from April 1993 to April 1994. Professor Gao worked in Medical Center of Duke University in the U.S. as an associate research professor of medicine from July 2002 to June 2011. Professor Gao served as a professor in Jilin University (吉林大學) in the PRC from December 2010 to November 2023. Professor Gao has been serving as an honorary professor in Medical Center of Duke University since September 2020 and a professor in Jinan University (暨南大學) in the PRC since October 2020.

Professor Gao obtained his bachelor's degree in medicine from Harbin Medical College (哈爾濱醫學院) (currently known as Harbin Medical University (哈爾濱醫科大學)) in the PRC in July 1984. Professor Gao obtained his master's degree in medicine from Chinese Academy of Preventive Medicine (中國預防醫學科學院) in the PRC in October 1987. Professor Gao participated in postdoctoral research in University of Birmingham, Alabama in the U.S.

Professor Gao has been serving as the vice chairman of Professional Committee of Immunity and Cell Therapy of Chinese Society of Laboratory Animals (中國實驗動物學會免疫與細胞治療專業委員會) and HIV Professional Committee of Chinese Association of STD and AIDS Prevention and Control (中國性病艾滋病防治協會艾滋病病毒專業委員會) since December 2018 and October 2020, respectively. He is also a standing member of Basic Research Professional Committee of Chinese Association of STD and AIDS Prevention and Control (中國性病艾滋病防治協會基礎研究專業委員會). Professor Gao has been serving as the vice chairman of Molecular Diagnostics Branch of China International Exchange and Promotive Association for Medical and Health Care (中國醫療保健國際交流促進會分子診斷學分會) since August 2022 and the executive president of Foshan Institute of Pathogenic Microbiology (佛山病原微生物研究院) since March 2023.

**Professor YUEN Ming Fai**, aged 73, was appointed as an independent Director on May 9, 2021 and re-designated as an independent non-executive Director on June 28, 2021. He is primarily responsible for supervising and providing independent judgement to our Board.

Prior to joining our Group, from November 1979 to December 1991, Prof. Yuen was appointed as a lecturer, and later senior lecturer at The University of Hong Kong. After that, Prof. Yuen worked for The Hong Kong University of Science and Technology (“**HKUST**”) from January 1992 to June 2016. During his tenure at HKUST, he had served as professor and head of the Department of Mechanical and Aerospace Engineering, professor of the Department of Biomedical Engineering, Director of the Technology Transfer Center, and Acting Vice-President (R&D) of HKUST. Prof. Yuen had also served at the HKUST R and D Corporation Ltd. (“**RDC**”) from January 2001 to June 2007 as vice president, and from April 2009 to November 2010 as the president and the chairman of the board of directors. He retired from HKUST in July 2016 and was appointed as a professor emeritus. From January 2017 to March 2022, Prof. Yuen was appointed as a specialist professor in Wuyi University (五邑大學).

Prof. Yuen served as an independent non-executive director of UDL Holdings Limited (太元集團有限公司) (currently known as DTXS Silk Road Investment Holdings Company Limited (大唐西市絲路投資控股有限公司)), a company listed on the Main Board of Stock Exchange (stock code: 620) from April 2002 to November 2015. Prof. Yuen also served as an independent non-executive director of CHTC Fong’s International Company Limited (中國恒天立信國際有限公司), a company listed on the Main Board of Stock Exchange (stock code: 641) from September 2004 to March 2022.

Prof. Yuen obtained his bachelor’s degree in mechanical engineering from The University of Hong Kong in October 1971 and obtained his doctoral degree in mechanical engineering from University of Bristol in the United Kingdom in October 1977.

## APPENDIX II BIOGRAPHIES OF NON-EMPLOYEE REPRESENTATIVE SUPERVISOR CANDIDATES OF THE SECOND SESSION OF THE SUPERVISORY BOARD

**Ms. QIAN Ranting**, aged 48, was appointed as a Supervisor on May 25, 2021. She is primarily responsible for overseeing the operations and financial affairs. Prior to joining our Group, Ms. Qian served as a managing director of Huiqiao Investment Advisory (Shanghai) Co., Ltd. (薈橋投資諮詢(上海)有限公司) from February 2018 to July 2019. She served as a director of Shanghai Duoning Biotechnology Co., Ltd. (上海多寧生物科技有限公司) from November 2018 to September 2022. She also served as a managing director of Shanghai Kuokun Investment Management Co., Ltd. (上海闊坤投資管理有限公司) from August 2019 to September 2020. She has served as a director of SMO Clinplus Co., Ltd., a company listed on the Shenzhen Stock Exchange (stock code: 301257) since March 2020, a director of Beijing WeMed Medical Equipment Co., Ltd. (北京唯邁醫療設備有限公司) since April 2021, a director of Jiangsu Synthgene Biotechnology Co., Ltd. (江蘇申基生物科技有限公司) since March 2022, and a director of Shanghai BangBang Robotics Co., Ltd. (上海邦邦機器人有限公司) since November 2022. Ms. Qian has been serving as the general manager and legal representative of Shanghai Hongjia Private Funds Management Co., Ltd. (上海弘甲私募基金管理有限公司) (previously known as Shanghai Hongjia Asset Management Co., Ltd. (上海弘甲資產管理有限公司)) since October 2020 and February 2022, respectively.

Ms. Qian obtained her bachelor's degree in economics from Beijing International Studies University (北京第二外國語學院) in the PRC in July 1997. Ms. Qian obtained her master of business administration from China Europe International Business School (中歐工商管理學院) in April 2004. Ms. Qian obtained her master in finance and development from University of London in the U.K. in December 2011. Ms. Qian has been a fellow member of the Association of Chartered Certified Accountants (FCCA) since March 2013.

**Mr. WANG Feizhou**, aged 56, was appointed as a Supervisor on June 17, 2022. Mr. Wang served as a teaching assistant at Jimei Navigation Institute (a predecessor of Navigation College of Jimei University) in Xiamen from August 1987 to March 1993, a lecturer at the School of Information Engineering of Jimei University in Xiamen from March 1993 to August 1998, a visiting scholar sponsored by the Ministry of Education of the PRC at the Centre for Transportation Studies of Nanyang Technological University in Singapore from July 1998 to July 1999, an associate professor at the School of Information Engineering of Jimei University in Xiamen from August 1999 to July 2013, a Telus technical specialist of ATI Group (a Canadian telecom company now merged into AFL Group) from February 2014 to September 2015, the risk control director and chief technical analyst of CAUS HOLDINGS GROUP CO., LTD. in Canada from September 2015 to September 2017, and a fund partner of Shanghai Zhongfu Venture Capital Management Co., Ltd. (上海中鵬創業投資管理有限公司) from January 2018 to October 2021. Mr. WANG Feizhou has been a co-founder and the chairman of the fourth session of the board of supervisors of 1029 CAFÉ SOCIETY, an entrepreneur club in Canada, since April 2015, and a co-founder and the chief technology officer of RAYSENSE TECHNOLOGY CONSULTING INC. in Canada since May 2018. Meanwhile, Mr. Wang has served as a fund partner and the legal representative of Jiangsu Zhongwei Tengyun Venture Capital Management Co., Ltd. (江蘇中衛騰雲創業投資管理有限公司) since May 2021 and August 2022, respectively.

Mr. WANG Feizhou obtained a bachelor's degree in radio communication engineering from Dalian Maritime University in 1987 and a master's degree in information engineering and control from Dalian Maritime University in 2000.